4.7 Article

Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove

Journal

JCI INSIGHT
Volume 8, Issue 4, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.156643

Keywords

-

Ask authors/readers for more resources

This study aimed to identify genetic variants contributing to the development of antidrug antibodies (ADA) against adalimumab, a widely used biologic in immune-mediated diseases. The study found a genome-wide association with ADA against adalimumab within the major histocompatibility complex (MHC) in psoriasis patients. The association was linked to specific amino acid residues in the HLA-DR peptide-binding groove, which conferred protection against ADA and treatment failure.
Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across immune-mediated diseases is adalimumab, a tumor necrosis factor inhibitor. This study aimed to identify genetic variants that contribute to the development of ADA against adalimumab, thereby influencing treatment failure. In patients with psoriasis on their first course of adalimumab, in whom serum ADA had been evaluated 6-36 months after starting treatment, we observed a genome-wide association with ADA against adalimumab within the major histocompatibility complex (MHC). The association signal mapped to the presence of tryptophan at position 9 and lysine at position 71 of the HLA-DR peptide-binding groove, with both residues conferring protection against ADA. Underscoring their clinical relevance, these residues were also protective against treatment failure. Our findings highlight antigenic peptide presentation via MHC class II as a critical mechanism in the development of ADA against biologic therapies and downstream treatment response.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available